Velocity Continues Rapid Growth with Luminis Health Partnership and Expansion into Oncology

Paul Evans, Velocity President and CEO, was featured in a Triangle Business Journal article covering Velocity’s recent partnership announcement with Luminis Health. As Paul notes in the article, hospitals play a crucial role in clinical research due to their patient populations, particularly in specialized fields like oncology. Velocity will take over the operation of the hospital’s … Read more

Dr. Kowdley Makes Significant Contributions to Pivotal Research Program for Ipsen’s Iqirvo for Primary Biliary Cholangitis

Kris Kowdley, MD, contributed significantly to the clinical research program that led to accelerated FDA approval of Ipsen’s Iqirvo, a first-in-class treatment for primary biliary cholangitis (PBC), a rare liver disease. As a primary investigator for the Phase 3 ELATIVE trial, Dr. Kowdley’s site enrolled the first patient in the study, and he was the … Read more

Velocity Partners with Luminis Health, Moves into Oncology in the U.S.

Velocity Clinical Research, the leading multi-specialty clinical sites business, and Luminis Health, a nonprofit health system providing care for 1.8 million people, today announce their partnership to conduct clinical research within the health group’s organization, connecting more patients with community-based research programs. The partnership will involve Velocity taking over operation of the hospital’s existing clinical … Read more

VISION Achieves 2,000 Patient Randomizations

Just one year ago, VISION technology empowered its first patient to self-screen and self-schedule a visit for a clinical trial at Velocity. In March, we announced that VISION had contributed to 1,000 patient randomizations, and that VISION Engage reached 50,000 app downloads. Today, VISION has contributed to more than 2,000 patient randomizations. VISION is making … Read more

Video: Participant Advisory Committee Meeting Insights

We can talk about elevating the patient’s voice in clinical research, or we can listen. So let’s listen! In this clip, you’ll hear from both current and past clinical trial participants. They share their first encounters with clinical research and the reasons they decided to participate. This compilation is from a recent Velocity Participant Advisory … Read more

Jerome Adams, MD, MPH, Provides Internal Presentation About the Importance of Diversity in Clinical Trial Inclusion

On May 30, Velocity welcomed former Surgeon General Jerome Adams, MD, MPH, to an internal presentation about the importance and direction of diversity in clinical trial inclusion, followed by a Q&A hosted by Paul Evans, President and CEO. The companywide meeting was the first of a three-part series that Velocity is hosting centered on inclusivity, … Read more

Raghu Punnamraju, Velocity CTO, On AI in Clinical Research

Velocity is using multimodal LLMs, like OpenAI’s GPT-4o and others, to enhance productivity. At the forefront of this shift is Raghu Punnamraju, Velocity’s Chief Technology Officer. In this article he shares his thoughts on the rapid evolution of LLMs, and how quickly new tools are being applied to improve quality and efficiency. We have been anticipating … Read more

Video: Velocity Site Tour

Enjoy a virtual tour of Velocity’s Durham, NC site, which showcases many of the features and standard equipment present at Velocity sites worldwide. Standard Velocity site features: Private exam rooms Comfortable patient reception areas Facilities for extended-stay PK studies Ample parking Secure monitoring rooms and workstations equipped with phones and high-speed internet Individual and secure … Read more

Video: Vaccine CARE Council Leader Mark Turner, MD

“Next to clean water, vaccines are probably responsible for more saved lives than anything else we’ve done in medicine.” -Mark Turner, MD, Vaccine CARE Council Leader and Velocity Principal Investigator in Boise, ID. Given the constant evolution of viruses and the massive medical and economic burdens imposed by viral diseases, vaccine research remains a global … Read more